5 not yet recruiting, 2 active not recruiting, 2 recruiting, 1 completed. 2 Not applicable, 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Not yet recruiting 2 |
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Esophageal Cancer (EsC): new trials by email Literature Review of Esophageal Cancer (EsC) trials Research Report on Esophageal Cancer (EsC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of VExUS Score on Postoperative Pulmonary Complications in Elderly Patients VExUS Score-Guided Intraoperative Goal-Directed Fluid Therapy - Esophageal Cancer (EsC), Postoperative Pulmonary Complications (PPCs) | Not yet recruiting | First Affiliated Hospital of Chongqing Medical University | 126 | 2026-08-01 | 2026-07-09 | |
| AI-Based Risk Prediction Model for Upper Digestive Tract Cancer Gastric Cancer (GC), Premalignant Lesion | Not yet recruiting | National Taiwan University Hospital | 10000 | 2026-05-18 | 2026-05-28 | |
| Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Trial Patient-Reported Outcome (PRO)-Based Symptom Management, Conventional Management - Esophageal Cancer (EsC) | Phase 3 | Not yet recruiting | Sichuan University | 240 | 2025-10-15 | 2025-10-07 |
| Health Informatics and Resistance Exercise for Symptom Management and Quality of Life in Post-Esophagectomy Patients symptom management health informatics plus Resistance band exercise training, Usual Care Group - Esophageal Cancer (EsC), Sarcopenia | Not applicable | Not yet recruiting | Chang Gung Memorial Hospital | 90 | 2025-10-01 | 2025-09-18 |
| Non-intubated Versus Intubated Anesthesia in Thoracoscopic Esophagectomy for Esophageal Cancer Non-intubated spontaneous ventilation anesthesia - Esophageal Cancer (EsC) | Not applicable | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 500 | 2025-10-01 | 2025-09-25 |
| INCIDENCE, PREVALENCE AND OVERALL RISK OF ESOPHAGEAL CANCER IN ACHALASIA: A PROPENSITY-MATCHED POPULATION-BASED STUDY FROM A LARGE MULTICENTER DATABASE achalasia treatments - Achalasia Cardia, Esophageal Cancer (EsC) | Active not recruiting | IRCCS San Raffaele | 47000 | 2025-06-03 | 2025-07-30 | |
| A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients radiotherapy, Immunotherapy, surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines - Esophageal Cancer (EsC) | Active not recruiting | Nanfang Hospital, Southern Medical University | 500 | 2025-04-15 | 2026-04-14 | |
| A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin - Esophageal Cancer (EsC) | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 30 | 2025-03-31 | 2025-10-02 |
| Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer Esophageal Cancer (EsC) | Recruiting | Semmelweis University | 100 | 2024-09-10 | 2026-04-24 | |
| Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer Nivolumab, Entinostat, Montanide(R) ISA-51 VG Adjuvant - Neoplasms, Esophageal Neoplasms | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-08-02 | 2024-08-05 | |
| Longitudinal Geriatric Vulnerability, Chemotherapy Toxicity, and Functional Outcomes in Older Adults With Gastrointestinal Cancer Standard-of-Care Systemic Chemotherapy - Gastrointestinal Cancers, Frailty | Completed | Ankara Etlik City Hospital | 132 | 2024-01-15 | 2026-10-16 |
Esophageal Neoplasms (11) · Sarcopenia (3) · Frailty (2) · Malnutrition (2) · Stomach Neoplasms (2) · Biliary Tract Neoplasms (1) · Cardiovascular Abnormalities (1) · Colorectal Neoplasms (1) · Esophageal Achalasia (1) · Gastritis, Atrophic (1) · Gastrointestinal Neoplasms (1) · Heart Failure (1) · Motor Activity (1) · Neoplasms (1) · Sarcoglycanopathies (1)
Digestive System Diseases (11) · Digestive System Neoplasms (11) · Esophageal Diseases (11) · Gastrointestinal Diseases (11) · Head and Neck Neoplasms (11) · Neoplasms by Site (11) · Gastrointestinal Neoplasms (10) · Neoplasms (10) · Atrophy (3) · Muscular Atrophy (3) · Nervous System Diseases (3) · Neurologic Manifestations (3) · Neuromuscular Manifestations (3) · Pathological Conditions, Anatomical (3) · Pathological Conditions, Signs and Symptoms (3)
130-nm albumin-bound paclitaxel (1) · Cisplatin (1) · Immunotherapy (1) · Nivolumab (1) · Patient Reported Outcome Measures (1) · Radiotherapy (1) · Surgical Procedures, Operative (1) · entinostat (1)
Ankara Etlik City Hospital (1) · Chang Gung Memorial Hospital (1) · First Affiliated Hospital of Chongqing Medical University (1) · IRCCS San Raffaele (1) · Nanfang Hospital, Southern Medical University (1) · National Cancer Institute (NCI) (1) · National Taiwan University Hospital (1) · Peking University Cancer Hospital & Institute (1) · Semmelweis University (1) · Sichuan University (1) · The First Affiliated Hospital of Guangzhou Medical University (1)
China (2) · Hungary (1) · Italy (1) · Turkey (Türkiye) (1) · United States (1)
Albert Jan Bredenoord, MD, PhD, Prof (1) · David S Schrump, M.D. (1) · Galip Can Uyar, MD (1) · Juying Jin (1)